84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]顧勇,趙艷明,童培建,等.基于數(shù)據(jù)挖掘法探討中藥復(fù)方治療股骨頭壞死的組方規(guī)律[J].中醫(yī)正骨,2021,33(06):49-53.
　GU Yong,ZHAO Yanming,TONG Peijian,et al.A study of medication rule of Traditional Chinese Medicine compounds for treatment of osteonecrosis of femoral head based on data mining approach[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(06):49-53.
點(diǎn)擊復(fù)制

基于數(shù)據(jù)挖掘法探討中藥復(fù)方治療股骨頭壞死的組方規(guī)律()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第33卷
期數(shù):
2021年06期
頁碼:
49-53
欄目:
數(shù)據(jù)庫研究
出版日期:
2021-06-20

文章信息/Info

Title:
A study of medication rule of Traditional Chinese Medicine compounds for treatment of osteonecrosis of femoral head based on data mining approach
作者:
顧勇1; 趙艷明1; 童培建2; 肖魯偉2
1.浙江中醫(yī)藥大學(xué)第一臨床醫(yī)學(xué)院,浙江 杭州 310053; 2.浙江省中醫(yī)院,浙江 杭州 310006
Author(s):
GU Yong1; ZHAO Yanming1; TONG Peijian2; XIAO Luwei2
1.The First Clinical Medical College of Zhejiang Chinese Medical University,Hangzhou 310053,Zhejiang,China 2.Zhejiang Provincial Hospital of Traditional Chinese Medicine,Hangzhou 310006,Zhejiang,China
關(guān)鍵詞:
股骨頭壞死;  中藥療法;  組方原則;  方劑分析; 計(jì)算機(jī)輔助;  數(shù)據(jù)挖掘;  聚類分析;  專利
Keywords:
femur head necrosis;  drug therapy(TCD);  formula composing principles;  formula anal comput assist;  data mining;  cluster analysis;  patents
摘要:
目的:探討中藥復(fù)方治療股骨頭壞死的組方規(guī)律。方法:檢索2000年11月1日至2020年10月31日,國家知識產(chǎn)權(quán)局中國專利公布公告網(wǎng)站(http://epub.cnipa.gov.cn)發(fā)布的含有中藥復(fù)方的治療股骨頭壞死(osteonecrosis of femoral head,ONFH)的專利。篩選檢索到的專利項(xiàng)目,將專利中中藥復(fù)方組成藥物的名稱規(guī)范后錄入Microsoft Excel 2010軟件和中醫(yī)傳承輔助平臺(V2.5),建立數(shù)據(jù)庫。對復(fù)方中中藥的性味歸經(jīng)及出現(xiàn)頻次進(jìn)行統(tǒng)計(jì),分析組方規(guī)律,并根據(jù)分析結(jié)果組合新方。結(jié)果:共納入184項(xiàng)專利,包含184個中藥復(fù)方,共有中藥640味。常用中藥有172味(出現(xiàn)頻次≥3次),藥性主要為溫、平,藥味主要為甘、苦、辛,歸經(jīng)多歸于肝、腎、脾經(jīng)。出現(xiàn)頻次較高的藥對由高至低依次為沒藥-乳香、骨碎補(bǔ)-當(dāng)歸、熟地黃-當(dāng)歸等,出現(xiàn)頻次較高的角藥由高至低依次為沒藥-乳香-當(dāng)歸、沒藥-乳香-骨碎補(bǔ)、紅花-沒藥-乳香等。分析得到藥物組合的13條關(guān)聯(lián)規(guī)則,置信度最高的關(guān)聯(lián)規(guī)則是乳香-骨碎補(bǔ)→沒藥; 關(guān)聯(lián)度最高的藥對是乳香-牛膝; 得到紅參-麝香-豬膽粉、黨參-淫羊藿-雞血藤、白術(shù)-川芎-茯苓等23條3味藥物的核心組合; 提取了8組新方藥物核心組合,組合了4個新方。結(jié)論:中藥復(fù)方治療ONFH,多采用藥性溫、平,藥味甘、苦、辛,歸肝、腎、脾經(jīng)的中藥; 以調(diào)補(bǔ)肝腎、活血化瘀、益氣健脾藥為主。
Abstract:
Objective:To explore the medication rule of Traditional Chinese Medicine(TCM)compounds for treatment of osteonecrosis of femoral head(ONFH).Methods:All authorized patents about TCM compounds for treatment of ONFH included from November 1,2000 to October 31,2020 were retrieved from the website(http://epub.cnipa.gov.cn)of China Patent Announcement of China National Intellectual Property Administration through computer.The obtained patents were screened,and the TCM compounds involved in the patents were extracted and their names were standardized and input into Microsoft Excel 2010 software and TCM inheritance support system(TCMISS)software(V2.5)to build the database.The statistics on property,flavour,meridian distribution and usage frequency of the TCM in compounds were conducted for analyzing medication rules and synthesizing new prescriptions.Results:One hundred and eighty-four patents were inculded in the final study,involving 184 TCM compounds and 640 TCMs,among which 172 ones were commonly used(occurrence frequency≥3 times),and they exhibited the drug property mainly as warm and normal,the drug flavours mainly as sweet,bitter and pungent,and the meridian distributions mainly as liver meridian,kidney meridian and spleen meridian.According to the occurrence frequency from high to low,the paired-herbs included Myrrh-Frankincense,Drynaria Fortunei-Chinese Angelica and Rehmanniae Radix Praeparata-Chinese Angelica; and the triplet-herbs included Myrrh-Frankincense-Chinese Angelica,Myrrh-Frankincense-Drynaria Fortunei and Carthamus Tinctorius-Myrrh-Frankincense in turn.Thirteen association rules of drug combinations were obtained through analysis,and the one with the highest confidence was Frankincense-Drynaria FortuneiMyrrh,and the paired-herbs with the highest correlation was Frankincense-Achyranthes Bidentata.Morover,23 core TCM combinations of triplet-herbs were obtained,including Radix Ginseng Rubra-Musk-Pulvis Fellis Suis,Codonopsis Pilosula-Epimedium-Caulis Spatholobi and Atractylodes Macrocephala Koidz-Ligusticum Chuanxiong-Poria Cocos,and 8 groups of core combinations of new prescriptions were extracted out,and 4 new prescriptions were synthesized.Conclusion:The TCM compounds exhibit the drug property mainly as warm and normal; the flavours mainly as sweet,bitter and pungent; the meridian distributions mainly as liver meridian,kidney meridian and spleen meridian; and the pharmacological actions mainly as liver-kidney-regulating,blood-activating and stasis-resolving as well as Qi-replenishing and spleen-invigorating in treatment of ONFH.

參考文獻(xiàn)/References:

[1] LESPASIO M J,SODHI N,MONT M A.Osteonecrosis of the hip:a primer[J].Perm J,2019,23:18-100.
[2] 宋夢歌,李記天,薛志鵬,等.股骨頭壞死保髖治療的臨床療效分析[J].中醫(yī)正骨,2020,32(1):36-39.
[3] 聶士超,鄔波.股骨頭壞死的治療進(jìn)展[J].中醫(yī)臨床研究,2018,10(30):144-148.
[4] 尹嘯飛,周正新.中醫(yī)藥治療股骨頭壞死臨床研究進(jìn)展[J].遼寧中醫(yī)藥大學(xué)學(xué)報,2018,20(2):218-221.
[5] 朱蜀云,楊康,王巍,等.股骨頭壞死中醫(yī)治法應(yīng)用分析[J].中醫(yī)正骨,2020,32(1):40-42.
[6] 唐仕歡,陳建新,楊洪軍,等.基于復(fù)雜系統(tǒng)熵聚類方法的中藥新藥處方發(fā)現(xiàn)研究思路[J].世界科學(xué)技術(shù)-中醫(yī)藥現(xiàn)代化,2009,11(2):225-228.
[7] SHENG H,SHENG C J,CHENG X Y,et al.Pathomorphological changes of bone marrow adipocytes in process of steroid-associated osteonecrosis[J].Int J Clin Exp Pathol,2013,6(6):1046-1050.
[8] 陳雷雷,何偉,張慶文,等.中醫(yī)藥治療股骨頭壞死臨床試驗(yàn)的系統(tǒng)評價[J].中華中醫(yī)藥雜志,2012,27(3):710-715.
[9] 趙寶祥.中醫(yī)辨證治療股骨頭壞死臨床研究[J].中醫(yī)學(xué)報,2015,30(8):1208-1210.
[10] YANG F,LIN Z W,HUANG T Y,et al.Ligustilide,a major bioactive component of angelica sinensis,promotes bone formation via the GPR30/EGFR pathway[J].Sci Rep,2019,9(1):6991.
[11] WANG D,LI J,FENG W Y,et al.Ligustilide suppresses RANKL-induced osteoclastogenesis and bone resorption via inhibition of RANK expression[J].J Cell Biochem,2019,120(11):18667-18677.
[12] 張巖巖,李靜,賈道勇,等.當(dāng)歸多糖對衰老模型小鼠造血干細(xì)胞Wnt/β-catenin信號通路的影響[J].中草藥,2015,46(14):2111-2116.
[13] 丁學(xué)蘭,趙信科,邱勇玉,等.當(dāng)歸多糖對環(huán)磷酰胺致骨髓抑制小鼠外周血細(xì)胞、免疫功能的影響[J].衛(wèi)生職業(yè)教育,2016,34(16):153-155.
[14] 王雨榕,鄧強(qiáng),李中鋒,等.中藥調(diào)節(jié)TGF-β表達(dá)促成骨作用治療骨質(zhì)疏松癥研究進(jìn)展[J].中國骨質(zhì)疏松雜志,2020,26(9):1391-1394.
[15] 韓宇,郭晏華,于艷.補(bǔ)骨脂甲素介導(dǎo)cAMP/PKA/CREB信號通路調(diào)控促進(jìn)骨髓MSC成骨分化作用研究[J].中華中醫(yī)藥學(xué)刊,2019,37(7):1597-1600.
[16] 李嘯群,徐凱航,紀(jì)方.補(bǔ)骨脂異黃酮抑制破骨細(xì)胞分化緩解小鼠去卵巢骨質(zhì)疏松[J].中國組織工程研究,2021,25(2):186-190.
[17] 李慧英,孟東方,阮志磊.骨碎補(bǔ)總黃酮對激素性股骨頭壞死血鈣、血磷及空骨陷窩率的影響[J].中華中醫(yī)藥雜志,2016,31(12):5352-5354.
[18] 申意偉,徐西林,張曉峰,等.骨碎補(bǔ)中柚皮苷治療股骨頭壞死研究進(jìn)展[J].遼寧中醫(yī)藥大學(xué)學(xué)報,2019,21(7):128-131.
[19] HU H,CHEN Y,ZOU Z,et al.Panax notoginseng saponins prevent bone loss by promoting angiogenesis in an osteoporotic mouse model[J/OL].Biomed Res Int,2020,10[2020-12-01].www.researchgate.net/publication/347629007_Panax_Notoginseng_Saponins_Prevent_Bone_Loss_by_Promoting_Angiogenesis_in_an_Osteoporotic_Mouse_Model.
[20] LIU S,YANG Y,QU Y,et al.Structural characterization of a novel polysaccharide from panax notoginseng residue and its immunomodulatory activity on bone marrow dendritic cells[J].Int J Biol Macromol,2020,161:797-809.
[21] 陳杰,張堃,孔令俊,等.三七總皂苷通過調(diào)控Wnt/β-catenin通路減輕家兔股骨頭壞死[J].中藥藥理與臨床,2019,35(4):95-99.
[22] 中華中醫(yī)藥學(xué)會.股骨頭壞死中醫(yī)辨證標(biāo)準(zhǔn)(2019年版)[J].中醫(yī)正骨,2019,31(6):1-2.

相似文獻(xiàn)/References:

[1]白春曉,賈育松,孫旗,等.中醫(yī)藥在腰椎間盤突出癥圍手術(shù)期應(yīng)用的研究進(jìn)展[J].中醫(yī)正骨,2015,27(11):65.
[2]江建春.神經(jīng)根型頸椎病的中醫(yī)藥治療研究概況[J].中醫(yī)正骨,2015,27(11):71.
[3]田正強(qiáng).消腫止痛散外敷聯(lián)合繃帶固定治療急性踝關(guān)節(jié)扭傷[J].中醫(yī)正骨,2015,27(10):28.
[4]劉枝城,董霞,謝正虎,等.手法整復(fù)小夾板鋼絲托板固定治療兒童新鮮孟氏骨折[J].中醫(yī)正骨,2015,27(10):55.
[5]沈海良,錢萬鋒,周驍棟.針刀松解聯(lián)合局部封閉與口服中藥治療腰椎間盤突出癥[J].中醫(yī)正骨,2015,27(09):46.
[6]徐西林,趙永蘭,張曉峰,等.活骨注射液髖關(guān)節(jié)腔灌注對兔股骨頭壞死模型 血管內(nèi)皮生長因子表達(dá)的動態(tài)影響[J].中醫(yī)正骨,2015,27(08):1.
　XU Xilin,ZHAO Yonglan,ZHANG Xiaofeng,et al.Dynamic effect of intra-articular hip injection of Huogu injection on the expression of vascular endothelial growth factor in rabbit models with femur head necrosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(06):1.
[7]周勇,任菲菲,豐凡翔,等.血管內(nèi)皮生長因子和骨形態(tài)發(fā)生蛋白2 在非創(chuàng)傷性股骨頭壞死不同區(qū)域的表達(dá)[J].中醫(yī)正骨,2015,27(08):7.
　ZHOU Yong,REN Feifei,FENG Fanxiang,et al.Expressions of vascular endothelial growth factor and bone morphogenetic protein 2 in different zones of femoral head with non-traumatic osteonecrosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(06):7.
[8]王建武,黨建軍,李強(qiáng),等.四聯(lián)療法治療膝骨關(guān)節(jié)炎[J].中醫(yī)正骨,2015,27(08):44.
[9]任博文,楊豪.口服桂葛萆薢湯加減配合功能鍛煉治療 寒濕型腰椎間盤突出癥[J].中醫(yī)正骨,2015,27(08):53.
[10]趙新杰,孫實(shí),武愛玲.中醫(yī)藥治療膝關(guān)節(jié)滑膜炎的研究進(jìn)展[J].中醫(yī)正骨,2015,27(08):65.
[11]陳雷雷,張穎.何偉教授采用中醫(yī)藥療法治療股骨頭壞死的經(jīng)驗(yàn)[J].中醫(yī)正骨,2015,27(10):74.
[12]胡海,豐凡翔,雷孝勇,等.中醫(yī)藥治療股骨頭壞死的常用藥物分析[J].中醫(yī)正骨,2016,28(08):24.
　HU Hai,FENG Fanxiang,LEI Xiaoyong,et al.Analysis of drugs commonly used in TCM therapy for treatment of osteonecrosis of the femoral head[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(06):24.
[13]姚晨,沈計(jì)榮,杜斌,等.口服補(bǔ)腎活血湯聯(lián)合微創(chuàng)保髖術(shù)治療股骨頭壞死腎虛血瘀證的臨床研究[J].中醫(yī)正骨,2016,28(11):7.
　YAO Chen,SHEN Jirong,DU Bin,et al.Clinical study on oral application of Bushen Huoxue Tang(補(bǔ)腎活血湯)combined with minimally invasive hip-preserving surgery for treatment of kidney-deficiency-blood-stasis-type osteonecrosis of femoral head[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(06):7.
[14]宋夢歌,李記天,薛志鵬,等.股骨頭壞死保髖治療的臨床療效分析[J].中醫(yī)正骨,2020,32(01):36.
[15]魏秋實(shí),李子祺,袁穎嘉,等.“標(biāo)本兼治”理論在股骨頭壞死中醫(yī)藥治療中的指導(dǎo)作用[J].中醫(yī)正骨,2020,32(01):56.
[16]張應(yīng)拴,邢濤,李盛華,等.名中醫(yī)治療股骨頭壞死的用藥規(guī)律分析[J].中醫(yī)正骨,2021,33(09):73.
　ZHANG Yingshuan,XING Tao,LI Shenghua,et al.Experience of prominent TCM doctors An analysis of clinical medication rules of prestigious TCM doctors in treatment of femur head necrosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(06):73.

備注/Memo

備注/Memo:
通訊作者:肖魯偉 E-mail:[email protected]
更新日期/Last Update: 2021-12-20